Literature DB >> 19474451

How I treat von Willebrand disease.

Francesco Rodeghiero1, Giancarlo Castaman, Alberto Tosetto.   

Abstract

Recent multicenter studies have clarified the molecular basis underlying the different von Willebrand disease (VWD) types, all of which are caused by the deficiency and/or abnormality of von Willebrand factor (VWF). These studies have suggested a unifying pathophysiologic concept. The diagnosis of VWD, remains difficult because its clinical and laboratory phenotype is very heterogeneous and may overlap with normal subjects. Stringent criteria are therefore required for a clinically useful diagnosis. In this paper, we delineate a practical approach to the diagnosis and treatment of VWD. Our approach is based on the critical importance of a standardized bleeding history that has been condensed into a final bleeding score and a few widely available laboratory tests, such as VWF ristocetin cofactor activity, VWF antigen and factor VIII. This approach would help identify those subjects who will probably benefit from a diagnosis of VWD. The next step involves performing a trial infusion with desmopressin in all patients who fail to exhibit an enhanced responsiveness to ristocetin. On the basis of these results and through a series of illustrative examples, the clinician will be able to select the best approach for the optimal management of VWD, according to the patient's characteristics and clinical circumstances.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19474451     DOI: 10.1182/blood-2009-01-153296

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease.

Authors:  V H Flood; J C Gill; P A Christopherson; J S Wren; K D Friedman; S L Haberichter; R G Hoffmann; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-07       Impact factor: 5.824

2.  Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults.

Authors:  Stefania Vaglio; Domenico Prisco; Gianni Biancofiore; Daniela Rafanelli; Paola Antonioli; Michele Lisanti; Lorenzo Andreani; Leonardo Basso; Claudio Velati; Giuliano Grazzini; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2015-12-15       Impact factor: 3.443

Review 3.  Continuing education course #2: current understanding of hemostasis.

Authors:  Andrew J Gale
Journal:  Toxicol Pathol       Date:  2010-11-30       Impact factor: 1.902

Review 4.  New treatment approaches to von Willebrand disease.

Authors:  Michelle Lavin; James S O'Donnell
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

5.  von Willebrand disease and von Willebrand factor.

Authors:  Brooke Sadler; Giancarlo Castaman; James S O'Donnell
Journal:  Haemophilia       Date:  2022-05       Impact factor: 4.263

Review 6.  von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.

Authors:  David Lillicrap
Journal:  Blood       Date:  2013-09-24       Impact factor: 22.113

Review 7.  Principles of care for the diagnosis and treatment of von Willebrand disease.

Authors:  Giancarlo Castaman; Anne Goodeve; Jeroen Eikenboom
Journal:  Haematologica       Date:  2013-05       Impact factor: 9.941

8.  Unnecessary Hysterectomy due to Menorrhagia and Disorders of Hemostasis: An Example of Overuse and Excessive Demand for Medical Services.

Authors:  Svetlana M Djukic; Danijela Lekovic; Nikola Jovic; Mirjana Varjacic
Journal:  Front Pharmacol       Date:  2016-12-23       Impact factor: 5.810

9.  Changes of von Willebrand Factor during Pregnancy in Women with and without von Willebrand Disease.

Authors:  Giancarlo Castaman
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-07-16       Impact factor: 2.576

Review 10.  Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A.

Authors:  Giancarlo Castaman; Silvia Linari
Journal:  Ther Clin Risk Manag       Date:  2016-06-30       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.